Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Dul7.0
Dulaglutid – Forschung
Überwiegend Mechanismus / Beobachtung
133 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Dulaglutid sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2012–2026 mit einer typischen Studiengröße von 255 Teilnehmenden.
Basierend auf 133 Studien · 13 Meta-Analysen · 104 RCTs · 92,241 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
Blood sugar & glycemic controlGroße, konsistente HbA1c-Senkungen im gesamten AWARD-Phase-3-Programm; überlegen gegenüber Insulin glargin und Exenatide · Wochen bis Monate
Überwiegend Mechanismus / Beobachtung102 Studien
Weight managementReale, aber moderate Gewichtsreduktion (typischerweise wenige Kilogramm, dosisabhängig) — geringer als Semaglutid im direkten Vergleich · Monate
Überwiegend Mechanismus / Beobachtung16 Studien
Cardiovascular outcomes12 % relative Reduktion schwerwiegender kardiovaskulärer Ereignisse in der dedizierten REWIND-Endpunktstudie (HR 0,88) · Monate bis Jahre
Überwiegend Mechanismus / Beobachtung15 Studien
Safety & adverse effects
Überwiegend Mechanismus / Beobachtung10 Studien
Aktives Forschungsgebiet
66 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
201220192026
1Meta-Analyse2016
Zhang L, Zhang M, Zhang Y, Tong N · Sci Rep (2016)
Einfach gesagt: Overall, GLP-1 receptor agonist treatment reduced MACE by 12% (HR 0.88, 95% CI 0.82-0.94; p<0.0001)... a broad composite kidney outcome by 17% (0.83, 0.78-0.89; p<0.0001)... There was no increase in risk of severe hypoglycaemia, pancreatitis, or pancreatic cancer.
Class-level 12% reduction in MACE (HR 0.88, 95% CI 0.82-0.94), with 12% lower cardiovascular and all-cause mortality and 9% fewer heart-failure hospitalizations
17% reduction in a composite kidney outcome (HR 0.83), mainly driven by reduced urinary albumin excretion
Einfach gesagt: Thus, it is crucial that patients and providers alike are aware of these AEs when considering their use.
Joy B, Ramsamooj A, Ibrahim S, Wen J, Hsu N, Frezza E. · Endocrine (2026)
Head-to-head comparisons revealed tirzepatide to carry the highest risk ratios for nausea and diarrhea while semaglutide carries the highest risk ratios for vomiting and constipation.
CONCLUSIONS: Regardless of the GLP-1 RAs used, it is apparent that GI AEs are significant and highly prevalent.
Thus, it is crucial that patients and providers alike are aware of these AEs when considering their use.
Einfach gesagt: Insulin regimens and specific glucagon-like peptide-1 receptor agonists (GLP-1 RAs) added to metformin-based background therapy produced the greatest reductions in hemoglobin A1c.
Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, Liakos A, Matthews DR, Bekiari E. · Ann Intern Med (2020)
Network meta-analysis of 453 trials assessing 21 antidiabetic interventions across 9 drug classes
GLP-1 receptor agonists (including dulaglutide) added to metformin-based therapy were among the most effective for HbA1c reduction
In patients at increased cardiovascular risk, specific GLP-1 RAs and SGLT2 inhibitors favorably affected vascular outcomes
Einfach gesagt: In conclusion, thevketogenic diet combined with dulaglutide can effectively improve glucose and lipid metabolism, insulin function and quality of life in diabetes mellitus patients.
Gao R, Yan L, Du X, He S, Xue L, Li T, Wei M, Gu Y. · Pakistan journal of pharmaceutical sciences (2025)
The results showed that, in comparison with the control group, the blood glucose and blood lipid levels in the study group were lower than those in the control group after treatment (P<0.05).
The insulin resistance index of the study group was decreased and the insulin sensitivity index was increased (P<0.05).
At the 6-month follow-up, the Pittsburgh Sleep Quality Index score was lower and the quality of life was better in the study group (P<0.05).
Einfach gesagt: Mazdutide was generally safe, although the incidence of gastrointestinal adverse events was higher for mazdutide than for dulaglutide.
Guo L, Zhang B, Xue X, Zhang X, Cai H, Jiang H, Zhang L, Jin P, Wang X, Cheng Z, Zhang S, Geng J, Guo Y, Hu H, Ma Q, Li L, Du H, Han-Zhang H, Xue F, Deng H, Qian L, Yang W, DREAMS-2 investigators. · Nature (2026)
Significantly greater reductions in body weight were achieved with mazdutide than with dulaglutide, with a least-squares mean treatment difference of -3.78% for 4 mg mazdutide and -5.76% for 6 mg mazdutide (both P < 0.0001), relative to dulaglutide.
Moreover, significantly more participants who received mazdutide 4 mg or 6 mg reached the composite end point of HbA 1c < 7.0% with a body-weight reduction of at least 5% at week 28 (both P < 0.0001), compared with those who received dulaglutide.
The most common treatment-emergent adverse events were diarrhoea, nausea and vomiting.
He Y, Mi N, Cheng Z, Xue H, Han J, Wang H, Wang H, Wu J, Shi X, Zhao S, Duan B, Zhu Y, Zhou Y, Li F, Wang X, Ling H, Wang S, Li Q, Jiang F, Yang M, Bing S, Zheng Q, Ning J, Guo M, Bu Y, Guan L, Li Y, Yang L, Guo W, Pan H, Li X. · The lancet. Diabetes & endocrinology (2025)
At week 32, mean HbA 1c reductions were 1·91% (SE 0·05; -20·86 mmol/mol [0·53]) with ecnoglutide 0·6 mg, 1·89% (0·05; -20·69 mmol/mol [0·54]) with ecnoglutide 1·2 mg, and 1·65% (0·05; -18·02 mmol/mol [0·53]) with dulaglutide.
Estimated treatment differences versus dulaglutide were -0·26% (95% CI -0·39 to -0·13; -2·84 mmol/mol [-4·29 to -1·38]) with ecnoglutide 0·6 mg and -0·24% (-0·38 to -0·11; -2·67 mmol/mol [-4·14 to -1·20]; p=0·0002 for superiority) with ecnoglutide 1·2 mg.
During the 52 weeks, six (3%) of 206 patients in the ecnoglutide 0·6 mg group, eight (4%) of 208 patients in the ecnoglutide 1·2 mg group, and six (3%) of 207 patients in the dulaglutide group discontinued treatment due to adverse events.
Corcoran E, Kettlety M, Mogul U, Azah JN, Cork SC. · Molecular and cellular neurosciences (2026)
While pre-clinical data has been encouraging, clinical evidence remains limited.
Conclusions There is consistent preclinical evidence that GLP-1R agonists are effective in reducing Aβ levels and hyperphosphorylated tau.
While the neuroprotective effect in preclinical studies is clear, clinical findings have so far failed to demonstrate an arresting effect on cognitive.